Fact-checked by Grok 2 weeks ago

Diffusing capacity for carbon monoxide

Diffusing capacity for (DLCO), also known as the transfer factor for (TLCO), is a pulmonary function test that quantifies the lung's ability to gas from the alveoli to the pulmonary capillary blood, specifically measuring the uptake of () per minute per unit of pressure gradient, typically expressed in ml/min/mmHg. It serves as a for oxygen , providing into the of the alveolar-capillary and pulmonary . DLCO is particularly valuable for diagnosing and monitoring conditions affecting , such as , interstitial lung disease, and pulmonary vascular disorders.

Fundamentals

Definition and Purpose

The diffusing capacity of the lung for (DLCO) is a key pulmonary function test that quantifies the lung's ability to transfer gas from the alveoli to the pulmonary . It represents the rate at which () is taken up by the per unit of pressure difference between the alveolar air and the , typically expressed in milliliters of per minute per millimeter of mercury (mL /min/mmHg). This measurement provides an indirect assessment of the efficiency of across the alveolar- membrane, encompassing both the diffusive properties of the membrane itself and the volume of available for gas binding in the pulmonary capillaries. The primary purpose of DLCO testing is to evaluate the integrity of the alveolar-capillary interface and the adequacy of pulmonary capillary blood volume, which are critical for effective oxygenation of blood. Clinically, it aids in the diagnosis and monitoring of various lung diseases, including restrictive disorders such as interstitial lung disease and pulmonary fibrosis, as well as certain obstructive conditions like emphysema, where reduced DLCO values indicate impaired gas transfer. By isolating the diffusive component of gas exchange, DLCO complements other spirometric measures like forced vital capacity and helps differentiate between parenchymal lung damage and vascular issues, such as pulmonary hypertension. DLCO was first described in 1915 by Danish physiologist Marie Krogh, who selected CO as the test gas due to its minimal endogenous production in the body and its high affinity for , which ensures that uptake is primarily limited by rather than reaction rates. This innovation allowed for the first quantitative evaluation of pulmonary in humans. Over the subsequent century, the test has evolved into a standardized procedure, with volumes reported under , dry (STPD) conditions to ensure comparability across measurements. Corrections for factors such as hemoglobin concentration and altitude are routinely applied to normalize results and account for physiological variations that influence CO binding.

Physiological Role in Gas Exchange

The for (DLCO) serves a key physiological role in evaluating the lung's capacity for during , particularly by approximating the diffusing capacity for oxygen (DL_O2). Both CO and O₂ are diffusion-limited gases that adhere to Fick's law of across the alveolar- , allowing DLCO to provide insight into the lung's ability to transfer O₂ from alveoli to pulmonary blood. In contrast, CO₂ exhibits much higher —approximately 20 times that of O₂—resulting in faster and making its transfer primarily perfusion-limited rather than diffusion-limited. According to Fick's law predictions, CO across the lung is about 83% that of O₂ due to differences in molecular weight and . DLCO integrates contributions from the alveolar-capillary membrane and the pulmonary , expressed through its primary components: the membrane diffusing capacity (), which reflects the surface area available for and the thickness of the blood-gas barrier, and the blood component (θVc), where θ represents the at which CO reacts with and Vc denotes the volume of in the pulmonary capillaries. The overall DLCO is related to these by the Roughton-Forster equation: \frac{1}{\text{DLCO}} = \frac{1}{\text{Dm}} + \frac{1}{\theta \text{Vc}} This formulation, established in seminal work on gas transfer kinetics, demonstrates how reductions in membrane area or increases in barrier thickness diminish Dm, while alterations in hemoglobin availability affect θ and thus the blood component. At its core, DLCO derives from Fick's law of diffusion, which quantifies the steady-state rate of gas transfer (V̇gas) as: \dot{V}_{\text{gas}} = A \cdot D \cdot \frac{(P_1 - P_2)}{T} Here, A is the effective surface area of the interface, D is the diffusion coefficient specific to the gas (influenced by its and molecular size), (P₁ - P₂) is the gradient driving , and T is the effective thickness of the diffusion barrier. To derive DLCO, this law is applied along the length of the pulmonary , where gas partial pressure in blood approaches exponentially with transit time; the overall capacity is then the of uptake to the driving pressure, standardized for a low test gas concentration to minimize back-pressure effects. This integration reveals DLCO as a conductance measure (mL/min/mmHg) that captures the lung's integrated diffusive efficiency for poorly soluble gases like O₂ and . Despite its utility, DLCO measurements are subject to physiological limitations related to hemoglobin binding dynamics. In anemia, reduced hemoglobin concentration lowers θ, decreasing the measured DLCO and causing it to underestimate the true diffusing capacity (Dm) unless adjusted using established correction formulas. Conversely, high states often increase DLCO due to greater pulmonary capillary (Vc), enhancing the blood component of gas transfer. These factors highlight the need to interpret DLCO in the context of systemic influences on blood reactivity and flow.

Measurement Techniques

Standard Procedure

The standard procedure for measuring diffusing capacity for carbon monoxide (DLCO) employs the single-breath technique, as outlined in the 2017 ERS/ATS technical standards. Patient preparation begins with ensuring no is required, though heavy meals should be avoided immediately prior to testing to prevent discomfort. Patients are instructed to abstain from for at least 24 hours beforehand to minimize elevated levels that could interfere with CO uptake measurements. The test is typically performed in a standardized sitting position, with the option to repeat in the if assessing positional changes in gas transfer; a nose clip and mouthpiece are applied for an airtight . Supplemental oxygen, if used, should be discontinued for at least 10-15 minutes prior, provided it is clinically safe. The procedure commences with the patient exhaling to residual volume. They then rapidly inhale a test gas mixture containing approximately 0.3% , 10% (as an inert tracer gas), 21% oxygen, and the balance , reaching total capacity () within 2-4 seconds, with inspired volume comprising at least 85-90% of . The breath is held for a standardized 10 seconds (±2 seconds), avoiding straining maneuvers such as Valsalva or Müller to ensure uniform distribution. Exhalation follows smoothly and rapidly to residual volume, with the initial 0.75-1.0 liter () discarded; an alveolar sample of 0.5-1.0 liter is then collected and analyzed for and concentrations using a gas analyzer or chromatograph. This process is repeated after a 4-minute interval to allow CO washout. Test reproducibility requires at least two acceptable maneuvers, with the two closest DLCO values within 2 mL·min⁻¹·mmHg⁻¹ (or 0.67 mmol·min⁻¹·kPa⁻¹) of each other, or within 10% for values below 20 mL·min⁻¹·mmHg⁻¹; up to five attempts may be made, but no more than two are averaged for reporting. Corrections are applied for environmental factors, including conversion to body temperature and pressure saturated (BTPS) conditions, adjustments for barometric pressure and , ambient temperature, and the inspired volume to estimate alveolar volume (). Safety considerations emphasize the low toxicity of the CO dose, which typically increases by only 0.5-1% per test, posing minimal risk to most patients. Absolute contraindications include recent or known toxicity, while relative contraindications encompass acute within the past month, severe , or inability to follow instructions due to . Potential side effects are rare but may include transient or mild . For non-cooperative patients unable to perform breath-holding, a rebreathing method serves as an alternative, involving continuous rebreathing of the gas mixture for 30-60 seconds in a closed circuit to achieve equilibration, though it requires different equipment calibration and is less commonly used in routine clinical settings.

Equipment and Calculations

The measurement of diffusing capacity for carbon monoxide (DLCO) requires specialized pulmonary function testing equipment to ensure accurate gas analysis, volume measurement, and data processing. Gas analyzers are essential for detecting carbon monoxide (CO) and the inert tracer gas, typically helium (He), with rapidly responding gas analyzers (RGAs) preferred in modern systems for their ability to provide continuous measurements during the breath-hold maneuver. These analyzers must meet performance criteria including a 0–90% response time of ≤150 ms, nonlinearity of ≤1% of full scale, accuracy within ±1%, and drift of ≤10 ppm for CO or ≤0.5% for the tracer gas over 30 seconds. Common types include non-dispersive infrared (NDIR) sensors for CO and thermal conductivity detectors for helium, though mass spectrometers offer high precision for simultaneous multi-gas analysis in advanced setups. Spirometers integrated into the system measure inspired and expired volumes, with flow sensors accurate to ±2% across -10 to +10 L/s and volume accuracy of ±75 when calibrated with a 3-L . These devices operate under body temperature and pressure saturated (BTPS) conditions to reflect physiological . Computer software is critical for signal alignment (gas and flow data digitized at ≥100 Hz with ≥14-bit resolution), automated calculations, and quality grading, often incorporating global lung function initiative () reference equations for interpretation. Dead-space volume in the equipment must be minimized to <200 for adults to avoid dilution errors. The primary calculation for DLCO derives from the single-breath method, quantifying CO uptake as the product of alveolar volume (VA) and the transfer coefficient (KCO). Specifically, \text{DLCO} = \frac{V_A}{t_{BH}} \times (P_B - P_{H_2O}) \times \ln\left(\frac{F_{I_{CO}}}{F_{A_{CO}} \times \frac{F_{A_{Tr}}}{F_{I_{Tr}}}}\right) where V_A is alveolar volume in liters (BTPS), t_{BH} is breath-hold time in seconds, P_B is barometric pressure in mmHg, P_{H_2O} is water vapor pressure in mmHg, F_{I_{CO}} is the inspired CO fraction, F_{A_{CO}} is the alveolar CO fraction at end-breath-hold, and F_{A_{Tr}} and F_{I_{Tr}} are the alveolar and inspired tracer gas fractions, respectively. This logarithmic form accounts for the exponential decay of CO during breath-holding, yielding DLCO in mL·min⁻¹·mmHg⁻¹ (or mmol·min⁻¹·kPa⁻¹ in SI units). An approximation for short breath-holds uses a linear difference: DLCO ≈ [VA × (F_{A_{CO,0}} - F_{A_{CO}})] / [ (P_B - P_{H_2O}) × t_{BH} / 760 ], but the full equation is standard for precision. Alveolar volume (VA) is estimated via single-breath dilution of the inert tracer gas (commonly 0.3% helium), reflecting the accessible gas-exchanging lung volume. The formula is V_A = (P_B - P_{H_2O}) \times V_I \times \frac{F_{I_{He}} - F_{A_{He}}}{F_{A_{He}}} where V_I is the inspired volume in liters (BTPS). This assumes negligible initial helium in the lung and corrects for dead-space contributions; in rapid gas analyzer systems, VA may incorporate mass balance from continuous exhaled tracer data for enhanced accuracy. VA is reported under BTPS conditions and typically ranges 4–6 L in healthy adults, directly influencing DLCO as it scales with lung size. Corrections adjust raw DLCO for physiological and environmental factors to standardize results. For hemoglobin (Hb), which affects CO binding, the correction is \text{DLCO}_{corr} = \text{DLCO} \times \frac{1.7 \times \text{Hb}}{10.22 + \text{Hb}} for adult males and adolescents (standard Hb = 14.6 g/dL), or \text{DLCO}_{corr} = \text{DLCO} \times \frac{1.7 \times \text{Hb}}{9.38 + \text{Hb}} for adult females and children under 15 years (standard Hb = 13.4 g/dL), with Hb measured in g/dL. This accounts for anemia or polycythemia, as DLCO varies linearly with Hb concentration in the R-state. For carboxyhemoglobin (COHb), back-pressure from endogenous CO reduces uptake; correction uses \text{DLCO}_{corr} = \text{DLCO} \times \left(1 + \frac{F_{A_{CO_b}}}{560}\right) where F_{A_{CO_b}} is the end-expiratory baseline CO fraction (often 0.5–1% in smokers), requiring co-oximetry measurement. Lung volume corrections are indirect, adjusting VA for predicted total lung capacity minus dead space if discrepancies arise, though no universal formula exists beyond ensuring full inspiration. Barometric pressure adjustments approximate DLCO scaling with (0.505 + 0.00065 × PB) for PB in mmHg. These are applied post-measurement using patient-specific data like recent Hb and COHb levels. Quality control follows ATS/ERS guidelines to ensure test acceptability and repeatability. Maneuvers are acceptable if there are no leaks (verified by volume stability), full inspiration achieves ≥90% of vital capacity (or ≥85% if VA is within 5% of the maximum), inspiration time is <4 seconds for ≥85% of VI, breath-hold duration is 8–12 seconds (10 ± 2 s), and exhalation sample collection is ≤4 seconds without Valsalva or glottis closure. At least two acceptable tests are required, with DLCO values repeatable within 2 mL·min⁻¹·mmHg⁻¹ (0.67 mmol·min⁻¹·kPa⁻¹) or <10% of the average. Systems grade maneuvers A–E based on criteria met, with A (all criteria) or B (minor deviations) usable for reporting the mean. Daily calibration with certified gases and biological controls (e.g., healthy subjects) maintains accuracy.

Underlying Mechanism

Principles of Diffusion

The diffusion of gases across the alveolar-capillary membrane in the lungs follows Fick's law of diffusion, which quantifies the rate of gas transfer as directly proportional to the surface area available for diffusion, the diffusion coefficient of the gas (a measure of its solubility and molecular mobility in the tissue), and the partial pressure gradient across the membrane, while being inversely proportional to the thickness of the diffusion barrier. This principle underpins the measurement of diffusing capacity for carbon monoxide (DLCO), where the overall transfer rate reflects the integrated effects of these biophysical factors in pulmonary gas exchange. In healthy lungs, CO diffusion is predominantly limited by the alveolar-capillary membrane rather than by the blood's capacity to bind CO, owing to the gas's high affinity for hemoglobin, which facilitates rapid uptake once CO reaches the red blood cells. This membrane limitation is described by the , which partitions DLCO into the membrane diffusing capacity (DM) and the blood component (θCO × Vc, where θCO is the rate of CO uptake by blood and Vc is pulmonary capillary blood volume):
\frac{1}{\text{DLCO}} = \frac{1}{\text{DM}} + \frac{1}{\theta_{\text{CO}} \cdot \text{Vc}}
Rearranging yields DM as
\text{DM} = \frac{\text{DLCO} \cdot \theta_{\text{CO}} \cdot \text{Vc}}{\theta_{\text{CO}} \cdot \text{Vc} - \text{DLCO}}
This formulation highlights how membrane properties dominate under normal conditions, with blood resistance contributing minimally to the total resistance for CO.
Historically, the diffusion properties of CO in lung tissue were quantified using Krogh's constant (K), defined as the product of the diffusion coefficient and solubility, representing the tissue's permeability to the gas; for CO, this value is approximately 0.0008 mL/min/mmHg/cm², as determined in early physiological studies of pulmonary diffusion. This constant provides a foundational metric for modeling gas permeation through lung parenchyma and informs modern interpretations of DLCO variability. Endogenous CO production from heme breakdown by heme oxygenase generates a small back pressure in the pulmonary capillaries (typically 0.3–0.5 mmHg partial pressure), which diminishes the effective partial pressure gradient for exogenous test CO and thereby reduces the measured DLCO by approximately 5–10% compared to the true diffusing capacity. This effect is routinely accounted for in clinical measurements through corrections based on estimated or measured carboxyhemoglobin levels.

Rationale for Using Carbon Monoxide

Carbon monoxide (CO) is selected for measuring diffusing capacity due to its exceptionally high affinity for hemoglobin, which is approximately 210 to 250 times greater than that of oxygen. This strong binding ensures that CO uptake is primarily limited by the diffusion properties of the alveolar-capillary membrane rather than by pulmonary blood flow or hemoglobin saturation levels, allowing for a more isolated assessment of the lung's membrane diffusing capacity. Additionally, CO exhibits low solubility in plasma, with a Bunsen solubility coefficient of 0.018 mL gas per mL plasma per atm, which minimizes the amount dissolved in the blood and emphasizes the role of trans-membrane diffusion over simple dissolution. Endogenous CO levels in the pulmonary capillaries are negligible, typically near zero partial pressure, creating a driving pressure gradient that approximates the inspired CO partial pressure minus zero, thereby simplifying the calculation of diffusing capacity without interference from back pressure. In contrast, using oxygen directly for such measurements is complicated by the variable saturation of hemoglobin along the capillary, which depends on local oxygen partial pressure and can confound the assessment of pure diffusion capacity. CO avoids this issue by maintaining near-complete binding due to its affinity, providing a purer evaluation of membrane conductance as a surrogate for oxygen transfer. To mitigate potential toxicity, the test employs a low CO concentration of 0.3% in the inspired gas mixture, resulting in a minimal increase in carboxyhemoglobin levels, typically less than 0.5% per test, which is safe and well below thresholds associated with physiological impairment.

Influencing Factors

Factors That Decrease DLCO

Several pathological conditions and physiological states can lead to a reduction in diffusing capacity for carbon monoxide (DLCO), primarily by impairing the alveolar-capillary membrane (Dm), pulmonary capillary blood volume (Vc), or the reaction rate of CO with hemoglobin (θ). In emphysema, a key component of chronic obstructive pulmonary disease (COPD), the destruction of alveolar walls results in a loss of surface area available for gas exchange, directly reducing Dm and overall DLCO. This structural damage limits the effective diffusion pathway, with DLCO often markedly reduced in moderate to severe cases compared to predicted values. Interstitial lung diseases (ILDs), such as , cause thickening of the alveolar-capillary membrane due to inflammation and fibrosis, which increases the diffusion distance for gases and impairs . This leads to a progressive decline in , serving as an early marker of disease severity. Anemia reduces θ, the rate at which CO binds to hemoglobin in red blood cells, because lower hemoglobin concentrations decrease the blood's capacity to carry CO, thereby lowering measured . This does not reflect intrinsic lung impairment, and correction formulas adjust raw DLCO values for hemoglobin levels to estimate true pulmonary diffusing capacity. Pulmonary hypertension diminishes Vc through vascular remodeling, vasoconstriction, and capillary destruction, which reduces the effective blood volume participating in gas exchange and thus decreases DLCO. This effect is particularly pronounced in pulmonary arterial hypertension, where capillary bed loss correlates with the severity of right ventricular strain. Other factors include transient reductions during high-altitude exposure, where hypocapnia from hyperventilation and acute hypoxia can impair diffusion dynamics, leading to a measurable drop in DLCO. Additionally, post-exercise fatigue causes a temporary 10-15% decrease in DLCO, attributed to pulmonary interstitial edema or reduced capillary recruitment following strenuous activity.

Factors That Increase DLCO

Polycythemia, characterized by an elevated red blood cell count and hemoglobin concentration, increases diffusing capacity for carbon monoxide (DLCO) primarily by enhancing the rate of CO binding to hemoglobin, denoted as θ in the , which directly elevates the θVc component where Vc represents pulmonary capillary blood volume. This physiological adaptation improves the overall capacity for gas transfer across the alveolar-capillary membrane, with studies reporting elevations up to approximately 20% in affected individuals compared to normal hemoglobin levels. In endurance-trained athletes, regular exercise training leads to structural adaptations in the pulmonary vasculature, including an expanded pulmonary capillary blood volume (Vc), which contributes to a 10-15% higher at rest and during submaximal exercise intensities compared to sedentary individuals. These changes arise from increased capillary recruitment and density in the lungs, optimizing gas exchange efficiency without significant alterations in membrane diffusing capacity () at baseline. The enhanced Vc allows for greater blood flow through the alveolar region, facilitating improved CO uptake and reflecting the lungs' adaptation to sustained high cardiac outputs during training. Mild asthma can result in supranormal DLCO values, often exceeding 120% of predicted norms, due to hyperinflation that enlarges alveolar surface area and promotes capillary recruitment through inflammatory processes. This hyperinflation, stemming from air trapping and increased lung volumes, effectively increases the effective diffusion surface for CO, distinguishing mild asthma from other obstructive diseases where DLCO is typically reduced. The associated mild inflammation further enhances pulmonary blood flow, amplifying the transfer factor without compromising overall ventilatory function. Left-to-right intracardiac shunts, such as those in atrial or ventricular septal defects, elevate DLCO by augmenting pulmonary blood flow, which distends and recruits additional pulmonary capillaries, thereby increasing Vc and the rate constant Kco (DLCO/VA). This hyperkinetic circulation redistributes blood volume more evenly across the lung fields, reducing diffusion resistance and boosting overall gas exchange capacity, often resulting in DLCO values well above predicted levels. The mechanism aligns with the Roughton-Forster model, where heightened Vc lowers the 1/θVc term, enhancing total DLCO. The supine position increases DLCO by 10-20% compared to the sitting posture in healthy individuals, primarily due to gravity-dependent pooling of blood in the pulmonary vasculature, which expands Vc particularly in dependent lung regions. This postural shift improves alveolar-capillary contact and uniformizes blood flow distribution, minimizing ventilation-perfusion mismatches that occur in upright positions. In endurance-trained athletes, the effect is more pronounced at rest, reflecting their greater baseline vascular compliance.

Clinical Interpretation

Normal Values and Variability

The diffusing capacity of the lung for carbon monoxide (DLCO) in healthy adults typically ranges from 20 to 30 mL/min/mmHg, with predicted values higher in men (mean approximately 28 mL/min/mmHg) than in women (mean approximately 21 mL/min/mmHg) when adjusted for age and height. These reference values are derived from large cohorts using standardized single-breath techniques and vary based on demographic factors, with equations incorporating age, sex, and height to generate individual predictions. DLCO declines gradually with age, at a rate of approximately 2-3% per decade after age 30, reflecting physiological changes in alveolar surface area and pulmonary capillary blood volume. Variability in DLCO measurements is inherent, with intra-subject reproducibility typically within 5-10% on repeat testing under controlled conditions, while inter-laboratory differences can reach up to 15% due to equipment and procedural variations. Natural variation is also influenced by factors such as sex, height, and ethnicity; for instance, African Americans exhibit predicted DLCO values about 10-15% lower than Caucasians of similar age, height, and sex, necessitating ethnicity-specific reference equations. The GLI-2017 equations are derived from Caucasian data, with adjustments recommended for other ethnicities, and ongoing research develops multi-ethnic references. In clinical practice, modern interpretation employs z-scores to assess deviation from predicted norms, with the lower limit of normal (LLN) defined as 1.64 standard deviations below the mean, corresponding to the 5th percentile in healthy populations and aiding in the identification of abnormality. Adjustments are routinely applied to raw DLCO measurements for hemoglobin concentration (using sex-specific equations to account for anemia effects), carboxyhemoglobin levels (correcting for back-pressure, particularly in smokers, at ~1% reduction per 1% COHb), and alveolar volume (VA) to normalize for lung size. The provides comprehensive reference equations incorporating these adjustments.
Age Group (years)Predicted DLCO (mL/min/mmHg) - Males (height 175 cm)Predicted DLCO (mL/min/mmHg) - Females (height 165 cm)
20-2930-3123-24
30-3929-3022-23
40-4928-2921-22
50-5927-2820-21
60+25-2719-21
Example predicted values based on GLI-2017 equations for non-smoking Caucasians; actual values require individual calculation via validated software. In pediatric populations, absolute DLCO values are lower than in adults but scale proportionally with body size, particularly height, reaching adult levels by late adolescence. Predicted norms for children and adolescents are provided by all-age reference sets like , which account for growth and yield values such as ~15-20 mL/min/mmHg in school-aged children, adjusted similarly for hemoglobin and VA.

Diagnostic Significance in Diseases

In obstructive lung diseases, DLCO is characteristically reduced in emphysema due to destruction of the alveolar-capillary membrane and loss of surface area for gas exchange, often distinguishing it from chronic bronchitis where DLCO remains normal or elevated because the pulmonary vasculature is largely intact. This pattern aids in subtyping chronic obstructive pulmonary disease (COPD), with low DLCO correlating to emphysematous changes and poorer prognosis. In restrictive lung diseases, DLCO is typically reduced proportionately to the loss of lung volume in interstitial lung diseases (ILD) such as idiopathic pulmonary fibrosis (IPF), where thickening of the alveolar-capillary barrier impairs diffusion; values often fall below 50% of predicted in advanced IPF. In contrast, DLCO is preserved or even elevated relative to alveolar volume in extrinsic restrictive conditions like neuromuscular disorders, as the membrane function remains intact despite reduced lung expansion. Cardiac-related conditions often show reduced DLCO due to loss of pulmonary capillary blood volume (Vc). In (PE), DLCO decreases primarily from impairment of the membrane diffusing capacity (DM), with reductions inversely related to the extent of embolism and persisting in cases with right ventricular dysfunction. Similarly, pulmonary edema reduces DLCO by disrupting the alveolar-capillary interface, though acute congestion may sometimes transiently increase it via vascular recruitment. Systemic diseases frequently manifest with low DLCO, reflecting associated pulmonary involvement. In HIV infection, DLCO impairment occurs independently of emphysema, with additive worsening in those with coexisting COPD, indicating direct effects on gas exchange surfaces. In scleroderma (systemic sclerosis), isolated DLCO reduction below 55% predicted at baseline predicts development of pre-capillary pulmonary arterial hypertension in up to 20% of cases over follow-up, underscoring its role in serial monitoring for progression. To differentiate membrane (DM) versus volume (Vc or VA) effects in combined disease patterns, the DLCO/VA ratio (KCO) is useful: a low KCO (<80% predicted) isolates intrinsic membrane damage as in emphysema or ILD, while a preserved or high KCO (>120%) suggests volume restriction without barrier impairment, as in . This ratio helps parse overlapping pathologies, avoiding overattribution to lung volume alone.

References

  1. [1]
    Diffusing Capacity of the Lungs for Carbon Monoxide - NCBI - NIH
    Oct 6, 2024 · The DLCO helps evaluate patients with dyspnea, hypoxemia, emphysema, and interstitial lung disease (ILD) and serves as an early indicator for ...Introduction · Procedures · Indications · Normal and Critical Findings
  2. [2]
    Lung Diffusion Testing (DLCO) - Cleveland Clinic
    The test measures how much carbon monoxide passes from your lungs to your blood, or the “diffusing capacity for carbon monoxide” (DLCO for short). What is ...
  3. [3]
    Carbon Monoxide Diffusing Capacity (DlCO) vs Kco & Va
    Dec 14, 2011 · The single-breath carbon monoxide diffusing capacity (DlCO) is the product of two measurements during breath holding at full inflation: (1) ...Changes in KCo and “Acces. · The Diffusing Capacity fo.<|control11|><|separator|>
  4. [4]
    [PDF] 2017 ERS/ATS standards for single-breath carbon monoxide uptake ...
    The abbreviation for transfer factor or diffusing capacity of the lung for carbon monoxide used in this document is DLCO, although TLCO is an equally valid term ...
  5. [5]
    One hundred years of pulmonary function testing - NIH
    Jan 15, 2015 · The single breath carbon monoxide (CO) diffusing capacity test (DLCO; or transfer factor TLCO) measures the alveolar surface area available ...Missing: definition | Show results with:definition
  6. [6]
    the carbon monoxide diffusing capacity (DLCO) and its ... - PubMed
    The single breath carbon monoxide diffusing capacity (DLCO sb), also called the transfer factor (TLCO), was introduced by Marie and August Krogh in two papers.
  7. [7]
    [PDF] the carbon monoxide diffusing capacity (DLCO) and its membrane ...
    The single breath carbon monoxide diffusing capacity (DLCO sb), also called the transfer factor (TLCO), was introduced by Marie and August Krogh in two ...
  8. [8]
    [PDF] The Physiologic Basis of DLCO testing | CACPT
    Gas exchange is a complex process. However, the use of DLCO to quantify the rate of gas exchange, although simplified and subject to various sources of ...
  9. [9]
    Single-breath DLCO maneuver causes cardiac output to fall during ...
    Because blood flow fell during the exercise and recovery breath-hold maneuver, the "true" DLCO may have been underestimated during and after cycling.
  10. [10]
  11. [11]
    [PDF] Single-Breath Carbon Monoxide Diffusing Capacity, 1999 Update
    2 a large meal or vigorous exercise immediately before the test;1. 5.2.3 smoking within 24 hours of test ad- ministration (smoking may have a direct effect on ...Missing: preparation abstinence
  12. [12]
    Adjustment of DLCO for hemoglobin concentration - PubMed
    The resulting equations for adjustment of DLCO (DLCOadj) to a standard [Hb] of 14.6 g/dl for men and 13.4 g/dl for women are: [equations: see text].
  13. [13]
    Physiology, Pulmonary Ventilation and Perfusion - StatPearls - NCBI
    One of the major roles of the lungs is to facilitate gas exchange ... DLCO provides insight into the alveolar area and thickness that impacts gas exchange.
  14. [14]
    Relative Importance of Diffusion and Chemical Reaction Rates in ...
    The Roughton-Forster equation for DL CO and DL NO re-examined. 1 Jul 2017 | Respiratory Physiology & Neurobiology, Vol. 241. The DL NO /DL CO ratio ...
  15. [15]
    On the .Rate of Diffusion of Carbonic Oxide into the Lungs of Man.
    Rate of Diffusion of Carbonic Oxide into the Lungs of Man.' BY. August Krogh and Marie Krogh. (From the Laboratory of Vegetable Physiology of Copenhagen ...
  16. [16]
    [PDF] The Roughton-Forster equation for DLCO and DLNO re-examined
    The partition ratios ␣CO = 0.018 and ␣NO = 0.041 (Cotes et al., 2006) were used. Three different geometries of gas-membrane-plasma-RBC structures are considered ...
  17. [17]
    Low diffusing capacity, emphysema, or pulmonary fibrosis - NIH
    DLCO values may decrease because of several clinical conditions including emphysema, interstitial lung diseases, or pulmonary fibrosis (2).
  18. [18]
    Using and Interpreting Carbon Monoxide Diffusing Capacity (Dlco ...
    Dlco is a calculated, derived value that indirectly assesses the ability of the lungs to “transfer” oxygen to blood through the use of a test gas.
  19. [19]
    Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in ...
    In patients with PAH, the primary cause of a low DLCO is a reduction in the pulmonary capillary blood volume, whereas in patients with IPF- PH, disorder/ ...
  20. [20]
    Acute high-altitude exposure reduces lung diffusion
    DLCO was lower at altitude due to DM reduction with a partially compensatory VC increase. •. Lung fluid increased at high altitude. •. No alveolar capillary ...
  21. [21]
    Decreased lung capillary blood volume post-exercise is ... - PubMed
    Compared with pre-exercise values, DLCO was depressed by up to 8.9 (3.0)% ( P<0.05) for the first 3 h following exercise, but had returned to pre-exercise ...Missing: transient percentage
  22. [22]
    Carbon monoxide diffusing capacity in polycythaemia rubra vera - NIH
    The diffusing capacity of the lung, or transfer factor, for carbon monoxide (TLCO) was measured in 12 patients with polycythaemia rubra vera.
  23. [23]
    Effect of aerobic fitness on capillary blood volume and diffusing ...
    During exercise, both groups exhibited increases in DLCO, D M and V C with exercise intensity. Athletes had a greater DLCO and greater D M at 80 and 90% of V ˙ ...
  24. [24]
    Effect of aerobic fitness on capillary blood volume and diffusing ...
    Mar 9, 2016 · Exercise diffusion capacity was greater in athletes, secondary to an increased membrane diffusing capacity, and not pulmonary capillary blood ...
  25. [25]
    Effects of Endurance Training Intensity on Pulmonary Diffusing ...
    Our findings suggest that the intensity of training may represent the most important factor in increasing pulmonary vascular function in young athletes.
  26. [26]
    Markedly Elevated DLCO in a Body Building Enthusiast - ATS Journals
    Elevated DLCO may result from asthma due to increased capillary recruitment or in states of high cardiac output with increased pulmonary blood flow.
  27. [27]
    Clinical significance of elevated diffusing capacity - PubMed - NIH
    A high DLCO on a PFT is most frequently associated with large lung volumes, obesity, and asthma. Other conditions are much less common.Missing: mild hyperinflation
  28. [28]
    Static lung volumes and diffusion capacity in adults 30 years after ...
    Aug 4, 2022 · In conclusion, this cross-sectional study shows that asthma is associated with a high DLCO and that longer asthma duration is associated with ...
  29. [29]
    Use and Interpretation of the Single-Breath Diffusing Capacity
    Left-to-right intracardiac shunts, as seen with atrial or ventricular septal defects, are characteristically associated with a high DLco, due to the significant ...
  30. [30]
    Effect of Postural Variations on Carbon Monoxide Diffusing Capacity ...
    Jun 5, 2008 · Results: In healthy individuals, DLCO tended to improve from the upright to the supine position (21.42 ± 2.90 and 26.07 ± 5.11 ml/min/mm Hg, ...
  31. [31]
  32. [32]
    A Comprehensive Review on Carbon Monoxide Diffusion Capacity ...
    Feb 3, 2024 · The anticipated normal values for DLCO in healthy nonsmoking adults highlight a mean DLCO of 28.05±5.07 mL/min/mmHg for men and 20.79±4.03 mL/ ...
  33. [33]
    Geriatric Respiratory Medicine - CHEST Journal
    For younger women 25 to 46 years of age, there was a lesser decline of 0.54 mL/min/mm Hg per decade, suggesting a protective hormonal effect prior to menopause.
  34. [34]
    Ethnic Differences in Pulmonary Function in Healthy Nonsmoking ...
    Accordingly, these studies have shown that whites have lung volumes 10–15% higher than blacks at a given standing height, and a “correction factor” of 10–15% is ...
  35. [35]
    Diffusing Capacity, the Too Often Ignored Lung Function Test in COPD
    More precisely, DLCO is useful in distinguishing patients with emphysema from those with predominantly airway disease (asthma or chronic bronchitis).
  36. [36]
    Measurement of Gas Exchange - Pulmonary Disorders
    Patients with anemia have lower DLCO values that correct when adjusted for hemoglobin values. Conditions that increase DLCO. Conditions that cause DLCO to be ...
  37. [37]
    Restrictive Lung Disease Workup - Medscape Reference
    Dec 2, 2024 · A normal DLCO value excludes intrinsic lung disease and indicates a chest wall, pleural, or neuromuscular cause of restrictive lung disease.
  38. [38]
    Reduction in membrane component of diffusing capacity is ...
    This study shows that diffusing capacity (DL,CO) and especially its alveolo-capillary membrane component (DM) are decreased in acute PE.
  39. [39]
    HIV Is Associated With Impaired Pulmonary Diffusing Capacity ... - NIH
    DLCO reflects abnormalities at the alveolar–capillary surface of the lungs, and there are several proposed pathways by which HIV may lead to abnormalities in ...
  40. [40]
    Predictive value of isolated DLCO reduction in systemic sclerosis ...
    Dec 23, 2015 · The objective was to investigate the prospective clinical relevance of isolated DLCO reduction at baseline in SSc patients.